Central Serous Chorioretinopathy Clinical Trial
— MICROPULSEOfficial title:
Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE
NCT number | NCT05679180 |
Other study ID # | CHUBX 2021/39 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | May 11, 2023 |
Est. completion date | May 24, 2023 |
Verified date | May 2023 |
Source | University Hospital, Bordeaux |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
MICROPULSE study aims to evaluate the efficacy of navigated microsecond laser (nMSL) for chronic central serous chorioretinopathy (CSCR).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 24, 2023 |
Est. primary completion date | May 24, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years and older - vision complaints for more than 6 weeks - subretinal fluid confirmed on OCT - diagnosis of CSCR confirmed by fluorescein and indocyanine green angiography - Signed informed consent - Affiliated or beneficiary of health insurance Exclusion Criteria: - History of treatment of CSC with other modalities (PDT, eplerenone) in the past 3 months - Other macular conditions : Age-related Macular Degeneration (AMD), polypoidal vasculopathy, choroidal neovascularization - Cataract or opacities interfering with acquisition or treatment - Myopia> 6 diopter - Visual acuity<20/200 - Treatment with steroids (per-os, inhaled or cutaneous) in the past 3 months - Intra-vitreal injections of anti-VEGF (Vascular Endothelial Growth Factor) or steroids in the past 3 months - History of allergy to fluorescein or indocyanine - Inability to agree to participate to the study - Pregnant or breastfeeding woman - Patient under legal protection |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | central macular thickness | central macular thickness measured in microns and determined on spectral-domain OCT | Month 3 | |
Secondary | central retinal thickness | central retinal thickness (micrometers) | Baseline, Month 3 | |
Secondary | visual acuity | visual acuity via ETDRS (Early Treatment of Diabetic Retinopathy Study) scale. The EDTRS scale is expressed in number of letters read. The scale is logarithmic, i.e. the progression between the 14 lines is geometric (by a factor equal to the cube root of 2). A loss of 3 lines of visual acuity thus corresponds to a doubling of the visual angle.This allows to determine the necessary corrections (sphere, cylinder, axis | Baseline, Month 3 | |
Secondary | eye sensitivity | eye sensitivity measured with microperimetry in decibels (dB) | Baseline, Month 3 | |
Secondary | presence of sub-retinal fluid | presence of sub-retinal fluid on Spectral-Domain Optical Coherence Tomography (SD-OCT) | Baseline, Month 3 | |
Secondary | presence of intraretinal cysts | presence of intraretinal cysts on SD-OCT | Baseline, Month 3 | |
Secondary | presence of flat irregular pigment epithelium detachment | presence of flat irregular pigment epithelium detachment (FIPED) on SD-OCT | Baseline, Month 3 | |
Secondary | presence of neovascularization | presence of type 1 neovascularization on OCT-angiography | Baseline, Month 3 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03497000 -
Effects of OCTA-guided PDT in Acute CSC
|
N/A | |
Recruiting |
NCT03692169 -
The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
|
||
Not yet recruiting |
NCT02215330 -
A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
|
Phase 2/Phase 3 | |
Completed |
NCT01971190 -
Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy
|
Phase 2 | |
Completed |
NCT01990677 -
Eplerenone for the Treatment of Central Serous Chorioretinopathy
|
N/A | |
Active, not recruiting |
NCT01710332 -
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
|
Phase 2 | |
Active, not recruiting |
NCT00403884 -
Selective RPE Laser Treatment (SRT) for Various Macular Diseases
|
N/A | |
Recruiting |
NCT05570591 -
Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy
|
N/A | |
Recruiting |
NCT05589974 -
Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
|
||
Completed |
NCT05104138 -
Eplerenone Versus PDT: Comparative Study by OCTA
|
||
Completed |
NCT01880788 -
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
|
N/A | |
Terminated |
NCT01982383 -
Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01327170 -
Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01019668 -
Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
|
N/A | |
Recruiting |
NCT06346405 -
Central Serous Chorioretinopathy and Micropulse Laser Treatment
|
||
Recruiting |
NCT02141308 -
OCT in Rare Chorioretinal Diseases
|
||
Completed |
NCT01822561 -
Eplerenone for Central Serous Chorioretinopathy
|
Phase 2 | |
Completed |
NCT00802906 -
Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)
|
N/A | |
Completed |
NCT05686421 -
Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations
|
N/A | |
Completed |
NCT03758963 -
Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy
|
N/A |